RT Journal Article
SR Electronic
T1 Outpatient and Home Pulmonary Rehabilitation Program Post COVID-19: A study protocol for clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.08.22273608
DO 10.1101/2022.04.08.22273608
A1 Oliveira, Luis V. F.
A1 Oliveira, Miriã C.
A1 Lino, Maria E. M.
A1 Carrijo, Marilucia M.
A1 Afonso, João Pedro R.
A1 Moura, Ricardo S.
A1 Fonseca, Adriano L.
A1 Fonseca, Daniela R. P.
A1 Oliveira, Luis Felipe R. J.
A1 Galvão, Letícia S.
A1 Reis, Bianca M.
A1 Diniz, Raphael H. C. O.
A1 Bernardes, Rubens R.
A1 Póvoa, Elisângela R. P.
A1 Silva, Anderson S.
A1 Santos, Dante B.
A1 Maldaner, Vinicius Z
A1 Coutinho, Jean Carlos
A1 Modesto, Guilherme Pacheco
A1 Oliveira-Silva, Iransé
A1 Lopes Martins, Rodrigo A. B.
A1 Lopes Martins, Patrícia S. L.
A1 Oliveira, Claudia S.
A1 Júnior, Gerson Cipriano
A1 Vieira, Rodolfo P
A1 Palma, Renata K.
A1 Alves, Larissa R.
A1 Insalaco, Giuseppe
YR 2022
UL http://medrxiv.org/content/early/2022/04/10/2022.04.08.22273608.abstract
AB Background The coronavirus disease 2019 (COVID-19) is a widespread, highly contagious inflammatory process that causes respiratory, physical and psychological dysfunction. COVID-19 mainly affects the respiratory system and evolves in the acute phase from mild cases with common symptoms, such as fever, cough, and fatigue, to the moderate-to-severe form, causing massive alveolar damage resulting in dyspnea and hypoxemia that can rapidly progress to pneumonia, and acute respiratory distress syndrome. The acute form usually causes severe pulmonary sequelae such as pulmonary fibrosis or progression to organ failure, leading to worsening metabolic dysfunction and/or death.Purpose To verify the effects of an outpatient and home pulmonary rehabilitation program (PRP) on clinical symptoms, pulmonary function, physical activity level, functional status, autonomic activity, peripheral muscle strength, static and functional balance, functional mobility, anxiety and depression, post-traumatic stress, health-related quality of life, and survival of patients with sequelae from COVID-19.Methods This study will be a cohort, parallel, two-arm multicentric study, to be carried out in three clinical centers, with blind evaluation, with 06 weeks of training and follow-up. This study was designed according to the recommendations of the CONSORT statement. To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19. The proposed PRP is based on the guidelines recommended by the Global Initiative for Chronic Obstructive Lung Disease and, consists of a combination of aerobic and muscle strengthening exercises, lasting six weeks, with a frequency of three times a week.Discussion In patients infected with COVID-19 with persistent symptoms and sequelae, PRP mainly seeks to improve dyspnea, relieve anxiety and depression, prevent, and reduce complications and/or dysfunctions, reduce morbidity and mortality, and improve health-related quality of life.Trial registration This study was registered at clinicaltrials.gov (ID: COVID-19 PULMONARY REHAB NCT04982042).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov (ID: COVID-19 PULMONARY REHAB - NCT04982042).Funding StatementThe funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures to be performed with the patients involved in this study are in accordance with international ethical standards for research involving human beings as per the 1964 Declaration of Helsinki and its subsequent amendments. This research protocol was approved by the Ethics Committee for Research with Human Beings of the Evangelical University of Goiás (UNIEVANGÉLICA) under protocol number 4.235.203. This clinical trial is registered at ClinicalTrials.gov (ID: COVID-19 PULMONARY REHAB - NCT04982042). Involvement in the study will be voluntary, and leave is allowed at any time without any burden. Participants will be required to sign the Informed Consent Form after receiving all information about the Pulmonary Rehabilitation Program.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion. https://www4.unievangelica.edu.br/ppg/movimento-humano-e-reabilitacao